Amylyx Pharmaceuticals, Inc.
AMLX Nasdaq
SEC CIK 1658551
Follow Amylyx Pharmaceuticals
Weekly email: filings, results
Net income
−$45.5M
−32.3% vs same quarter last year
EPS, diluted
−$0.38
−2.7% vs same quarter last year
Operating cash flow
−$33.7M
−10.9% vs same quarter last year
Operating income
−$49.7M
−37.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$144.7M |
| FY24 | $87.4M | −$301.7M |
| FY23 | $380.8M | $49.3M |
| FY22 | $22.2M | −$198.4M |
| FY21 | $285K | −$87.9M |
| FY20 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | - | - |
| FY24 | 93.2% | −360.2% | −345.4% |
| FY23 | 93.3% | 10.2% | 12.9% |
| FY22 | 86.5% | −905.7% | −892.4% |
| FY21 | - | −29013.3% | −30853% |
| FY20 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$123.5M |
| FY24 | −$167.8M |
| FY23 | $10.7M |
| FY22 | −$182.4M |
| FY21 | −$75.2M |
| FY20 | - |
- Amylyx Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Amylyx Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | −345.4% | −47% |
| FY23 | 12.9% | −58% |
| FY22 | −892.4% | −80.4% |
| FY21 | −30853% | −71.9% |
| FY20 | - | −62.2% |